News
MTRI
16.00
+2.83%
0.44
Press Release: Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing
Dow Jones · 18h ago
Press Release: Mentari Therapeutics Announces -2-
Dow Jones · 18h ago
Weekly Report: what happened at INM last week (1102-1106)?
Weekly Report · 20h ago
*InMed Pharmaceuticals: Mentari Therapeutics Shares Expected to Begin Trading on Nasdaq Capital Market Under Symbol MTRI Starting Nov. 9>INM
Dow Jones · 3d ago
*InMed Pharmaceuticals Completes Closing Of Merger With Mentari Therapeutics >INM
Dow Jones · 3d ago
Press Release: InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics
Dow Jones · 3d ago
InMed Pharmaceuticals Inc. Announces Name Change to Mentari Therapeutics, Inc. and Share Consolidation
NASDAQ · 4d ago
InMed expects to start trading as Mentari Therapeutics on November 9
TipRanks · 4d ago
InMed Pharmaceuticals Inc trading resumes
TipRanks · 4d ago
InMed Pharmaceuticals Inc trading halted, volatility trading pause
TipRanks · 4d ago
InMed Pharmaceuticals Inc. Announces Name Change, Share Consolidation and Shareholder Approval of Mentari Merger
NASDAQ · 4d ago
InMed Pharmaceuticals Completes Share Consolidation and Name Change
TipRanks · 4d ago
InMed Pharmaceuticals Inc trading halted, news pending
TipRanks · 5d ago
InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation
Newsfile · 5d ago
InMed Advances Mentari Merger Amid Nasdaq Compliance Review
TipRanks · 6d ago
InMed Pharmaceuticals Q1 EPS $(0.36) Up From $(0.46) YoY
Benzinga · 6d ago
InMed Pharmaceuticals reports Q1 EPS (42c) vs (44c) last year
TipRanks · 6d ago
InMed Pharmaceuticals GAAP EPS of -$0.36
Seeking Alpha · 6d ago
InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update
Newsfile · 6d ago
InMed Announces Proposed Ten-for-One Share Consolidation
TipRanks · 11/02 22:53
More
Webull provides a variety of real-time MTRI stock news. You can receive the latest news about Mentari Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MTRI
Mentari Therapeutics, Inc., formerly InMed Pharmaceuticals Inc., is a biotechnology company developing therapies for migraine prevention. The Company's lead programs target PACAP, a newly validated target that is mechanistically independent from calcitonin gene-related peptide (CGRP). Its pipeline includes MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing, and MT-002, an anti-CGRP and anti-PACAP bispecific antibody designed to inhibit these complementary pathways with the potential to deliver superior outcomes for people with incomplete response to CGRP-targeted therapies.